Teachers Retirement System of The State of Kentucky Decreases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Teachers Retirement System of The State of Kentucky lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 127,202 shares of the medical device company’s stock after selling 7,404 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in DexCom were worth $17,643,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Crewe Advisors LLC bought a new stake in DexCom in the 1st quarter worth approximately $29,000. DSM Capital Partners LLC bought a new stake in shares of DexCom in the fourth quarter worth $28,000. Riverview Trust Co purchased a new stake in DexCom during the first quarter valued at $32,000. Valley National Advisers Inc. lifted its holdings in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the period. Finally, MV Capital Management Inc. boosted its position in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Redburn Atlantic began coverage on shares of DexCom in a research report on Thursday, May 30th. They set a “neutral” rating and a $130.00 price target for the company. Stifel Nicolaus decreased their price target on shares of DexCom from $132.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Barclays cut their price objective on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Robert W. Baird cut DexCom from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $161.00 to $80.00 in a report on Friday, July 26th. Finally, BTIG Research lowered their target price on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $111.50.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Friday, May 31st. The shares were sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the transaction, the executive vice president now directly owns 67,560 shares of the company’s stock, valued at $8,055,854.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other DexCom news, EVP Sadie Stern sold 427 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Michael Jon Brown sold 652 shares of DexCom stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $119.24, for a total value of $77,744.48. Following the completion of the transaction, the executive vice president now owns 67,560 shares of the company’s stock, valued at approximately $8,055,854.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,135 shares of company stock valued at $446,797. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

DXCM traded up $1.98 during trading on Friday, reaching $72.30. 7,633,973 shares of the company traded hands, compared to its average volume of 7,607,828. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a fifty day simple moving average of $109.33 and a 200 day simple moving average of $121.82. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The company has a market cap of $28.97 billion, a P/E ratio of 46.65, a PEG ratio of 2.18 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. During the same period last year, the company posted $0.34 earnings per share. On average, equities analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.